Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Mulls Clinical Studies, Labeling For Over-The-Counter HIV Tests

This article was originally published in The Gray Sheet

Executive Summary

Over-the-counter (OTC) HIV test kits would answer an unmet need, but clinical trials and product labeling must be carefully crafted to ensure that benefits outweigh the risks, according to FDA's Blood Products Advisory Committee
Advertisement

Related Content

OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
Demand For Rapid HIV Testing On The Rise
Demand For Rapid HIV Testing On The Rise
Chembio Joins The Race For Over-The-Counter HIV Test
OraSure’s Over-The-Counter HIV Test Could Begin Trials This Summer
OTC HIV Tests
OraSure Seeks Panel Feedback On Marketing Of Home-Use HIV Test
OraSure Seeks Panel Feedback On Marketing Of Home-Use HIV Test
Advertisement
UsernamePublicRestriction

Register

MT022863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel